Effects of Antrodia Cinnamomea on the Hepatoma Patients After Transcatheter Hepatic Artery Chemoembolization
Taichung Tzu Chi Hospital
60 participants
Jan 1, 2023
INTERVENTIONAL
Conditions
Summary
Effects of Antrodia cinnamomea on the hepatoma patients after Transcatheter hepatic artery chemoembolization
Eligibility
Inclusion Criteria4
- Sign the informed consent form
- Aged between 20 and 80
- Child-Pugh score class A, B
- Serum bilirubin level ≤ 1.5 times the upper limit of normal, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels ≤ 2 times the upper limit of normal
Exclusion Criteria13
- Unwillingness to sign the informed consent form
- Child-Pugh score class C
- Patients with main portal vein thrombosis
- Patients with diffuse liver tumors
- Those who are allergic to the contrast medium
- Those with abnormal coagulation function
- Those with severe dysfunction of brain, heart and lung
- Patients with severe renal dysfunction (except those receiving renal dialysis)
- Unable to cooperate
- Those with uncontrolled arrhythmia and unstable blood pressure
- Some patients with abnormal thyroid function
- Any other contraindications such as active gastrointestinal bleeding, refractory ascites, or severe portal hypertension
- Pregnant or lactating women
Interventions
The experiment lasted for 11 days, and patients were required to take Kangjian Antrodia cinnamomea 3 days before embolization, the day of embolization to the 7th day after surgery, once a day in the morning and evening after meals, 2 capsules each time.
The experiment lasted for 11 days, and patients were required to take placebo 3 days before embolization, the day of embolization to the 7th day after surgery, once a day in the morning and evening after meals, 2 capsules each time.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07178093